Abstract
We report two cases of non-cardiogenic pulmonary edema as a complication of basiliximab induction therapy in young pediatric renal transplant patients identified following a retrospective review of all pediatric renal transplant cases performed in the National Paediatric Transplant Centre, Childrens University Hospital, Temple Street, Dublin, Ireland. Twenty-eight renal transplantations, of which five were living-related (LRD) and 23 were from deceased donors (DD), were performed in 28 children between 2003 and 2006. In six cases, transplantations were pre-emptive. Immunosuppression was induced pre-operatively using a combination of basiliximab, tacrolimus and methylprednisolone in all patients. Basiliximab induction was initiated 2 h prior to surgery in all cases and, in 26 patients, basiliximab was re-administered on post-operative day 4. Two patients, one LRD and one DD, aged 6 and 11 years, respectively, developed acute non-cardiogenic pulmonary edema within 36 h of surgery. Renal dysplasia was identified as the primary etiological factor for renal failure in both cases. Both children required assisted ventilation for between 4 and 6 days. While both grafts had primary function, the DD transplant patient subsequently developed acute tubular necrosis and was eventually lost within 3 weeks due to thrombotic microangiopathy and severe acute antibody-mediated rejection despite adequate immunosuppression. Non-cardiogenic pulmonary edema is a potentially devastating post-operative complication of basiliximab induction therapy in young pediatric patients following renal transplantation. Early recognition and appropriate supportive therapy is vital for patient and, where possible, graft survival.
References
Pape L, Strehlau HT, Latta K, Nashan B, Ehrich JH, Klempnauer J, Offner G (2002) Single centre experience with basiliximab in paediatric renal transplantation. Nephrol Dial Transplant 17:276–280
Maes BD, Vanrenterghem YF (1999) Anti- interleukin-2 receptor monoclonal antibodies in renal transplantation. Nephrol Dial Transplant 14:2824–2826
Lee BM, Oh CK, Jin SH, Kim JH, Kim SJ, Kim H, Shin GT (2006) Effect of basiliximab on renal allograft rejection within 1 year after transplantation. Transplant Proc 38:2025–2028
Matas AJ, Gillingham KJ, Payne WD, Najarian JS (1994) The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 57:857
Keown P, Niese D (1998) Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group. Kidney Int 54:938–944
Bamgbola FO, Del Rio M, Kaskel FJ, Flynn JT (2003) Non cardiogenic pulmonary edema during basiliximab induction in three adolescent renal transplant patients. Pediatr Transplant 7:315–320
Lauzurica R, Pastor MC, Bayes B, Hernandez JM, Bonet J, Doladé M, Navarro M, Romero R (2008) Pretransplant inflammation: a risk factor for delayed graft function? J Nephrol 21:221–228
Steinberg KP, Hudson LD (2000) Acute lung injury and acute respiratory distress syndrome: the clinical syndrome. Clin Chest Med 21:401–417
Duzova A, Buyan N, Bakkaloglu M, Dalgic A, Soylemezoglu O, Besbas N, Bakkaloglu A (2003) Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year. Transplant Proc 35:2878–2880
Garcia-Meseguer C, Roldan M, Melgosa M, Alonso A, Peña A, Espìnosa L, Navarro M (2002) Efficacy and safety of basiliximab in pediatric renal transplantation. Transplant Proc 34:102–103
Swiatecka-Urban A, Garcia C, Feuerstein D, Suzuki S, Devarajan P, Schechner R, Greenstein S, Tellis V, Kaskel F (2002) Basiliximab induction improves the outcome of renal transplants in children and adolescents. Pediatr Nephrol 16:693–696
Kandus A (2002) Preventing Acute Rejection with Basiliximab and triple immunosuppression after renal transplantation. Transplant Proc 34:2907–2909
Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP, CHIB 201 International Study Group (1997) Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 350:1193–1198
Crimi E, Slutsky AS (2004) Inflammation and the acute respiratory distress syndrome. Best Pract Res Clin Anaesthesiol 18:477–492
Vincenti F (2001) Action, efficacy and toxicities: anti-CD25 monoclonal antibodies. In: Norman DJ, Turka LA (eds) Primer on transplantation, 2nd edn. American Society of Transplantation, Mount Laurel
Jackson FN, Rowland V, Corssen G (1980) Laryngospasm-induced pulmonary edema. Chest 78:819–821
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dolan, N., Waldron, M., O’Connell, M. et al. Basiliximab induced non-cardiogenic pulmonary edema in two pediatric renal transplant recipients. Pediatr Nephrol 24, 2261–2265 (2009). https://doi.org/10.1007/s00467-009-1244-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-009-1244-4